ArticleCurrent medical science2018
Clinicopathological Characteristics and Prognosis of Hepatoid Adenocarcinoma of the Stomach: Evaluation of a Pooled Case Series.
Article in Current medical science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinicopathological features of hepatoid adenocarcinoma and non-hepatoid adenocarcinoma of the stomach: A systematic review and meta-analysis.Cancer medicine · 2024Pooled it
- Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach.International journal of biological sciences · 2022Pooled it
- The role ofAbdominal radiology (New York) · 2026Article
- Immunotherapy-based neoadjuvant treatment of gastric cancer with elevated serum AFP: a case report.Journal of medical case reports · 2026Article
- Diagnostic dilemmas in hepatoid adenocarcinoma of the stomach: Navigating clinical and pathological loopholes.World journal of methodology · 2026Review
- A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series.Cancer medicine · 2026Review
- Spontaneous rupture of hepatic metastasis as the initial presentation of gastric hepatoid adenocarcinoma: a rare case report and literature review.Frontiers in oncology · 2026Article
- Case Report: Second-line favourable effect of pembrolizumab plus chemotherapy in a patient with metastatic hepatoid adenocarcinoma of the stomach.Frontiers in pharmacology · 2025Article
- Clinicopathological characteristics and prognostic outcomes of resectable hepatoid adenocarcinoma of the stomach: insights from a multicenter case-control study.American journal of cancer research · 2025Article
- Rare epithelial gastric cancers: a review of the current treatment knowledge.Therapeutic advances in medical oncology · 2025Review
- Case Report: Pathologic complete response to PRaG therapy in an elderly patient with refractory metastatic gastric cancer.Frontiers in oncology · 2025Article
- [Primary uterine hepatoid adenocarcinoma: Clinicopathological analysis of 2 cases and literature review].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Review
- Development of dynamic nomogram for predicting cancer-specific survival in hepatoid adenocarcinoma: A comprehensive SEER-based population analysis.Biomolecules & biomedicine · 2024Article
- Clinicopathological features of hepatoid adenocarcinoma of the stomach: A multicenter retrospective study.Cancer reports (Hoboken, N.J.) · 2024Article
- Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report.Frontiers in immunology · 2024Article
- Hepatoid adenocarcinoma of the stomach with neuroendocrine differentiation: A case report and review of literature.World journal of clinical cases · 2023Article
- Emphasis on the clinical relationship between alpha-fetoprotein and hepatoid adenocarcinoma of the stomach: a retrospective study.BMC gastroenterology · 2023Article
- Prognostic significance of preoperative serum tumor markers in hepatoid adenocarcinoma of stomach (HAS).BMC cancer · 2023Article
- Pathologic complete response of hepatoid adenocarcinoma of the stomach after chemo-immunotherapy: A rare case report and literature review.Frontiers in surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoid adenocarcinoma of the stomach (HAS) is an extremely rare and unique gastric malignancy. The present study aimed to examine the relevance of the clinicopathological characteristics of HAS with patient prognosis. We retrospectively reviewed clinical data of 34 HAS patients treated at our institution between January 2010 and December 2016, as well as 294 cases reported prior to 2017 in research databases. Among these patients, 45.6% (115/252) had lesions in the gastric antrum and 77.0% (235/305) were male. Elevated levels of serum alpha-fetoprotein (AFP) were detected in most patients (75/93, 80.6%). Vascular invasion (199/286, 69.6%), lymph node metastasis (222/283, 78.4%), and preoperative distant metastasis (121/328, 36.9%) were commonly observed. The 5-year disease-free survival (DFS) and disease-specific survival (DSS) were 20.7% and 29.2%, respectively. DFS and DSS of patients receiving neoadjuvant therapy were significantly higher than those of patients receiving postoperative adjuvant therapy [DFS: P<0.001, hazard ratio (HR)=-1.831, 95% confidence interval (CI): 0.060-0.429; DSS: P<0.001, HR=-2.185, 95% CI: 0.032-0.401]. In conclusion, HAS exhibits distinct clinicopathological characteristics and a strikingly worse prognosis when compared with common gastric cancer. Complete surgery, early pTNM stage, and adjuvant therapy may predict a more favorable prognosis. Neoadjuvant therapy is strongly recommended for patients with lymph node metastasis or/and preoperative distant metastasis.
Indexed as
Identifiers
30536069What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.